Biotechnology Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter – Corcept Therapeutics (NASDAQ:CORT) Read more
Biotechnology Spruce Biosciences’ Hormone Treatment Stumbles In Trials, Prompts Stock Freefall Spruce Biosciences’ Hormonal Disorder Candidate’s Future in Limbo: Analysts Downgrade Amid Tildacerfont’s Trial Setback – Spruce Biosciences (NASDAQ:SPRB) Read more